A Randomized, Parallel-group, Placebo-controlled Subject and Investigator Blinded Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of QCC374 in the Treatment of Pulmonary Arterial Hypertension
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Apr 2017
At a glance
- Drugs QCC 374 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 29 Mar 2017 Planned End Date changed from 1 Feb 2019 to 25 Apr 2019.
- 29 Mar 2017 Planned primary completion date changed from 1 Feb 2019 to 26 Mar 2019.
- 29 Mar 2017 Planned initiation date changed from 1 Mar 2017 to 15 May 2017.